title: Safety, pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple-dose administration to healthy Chinese subjects.
abstract: Batifiban, a synthetic cyclic peptide, is a potent platelet glycoprotein GPIIb/IIIa antagonist which may be useful in the treatment and prevention of acute coronary syndromes. The pharmacokinetics and pharmacodymanic (inhibition of platelet aggregation) effects, and tolerability of batifiban were investigated in healthy subjects following single bolus injection with doses of 55, 110, or 220 microg/kg, or multiple doses of an bolus followed intravenous infusion for 24 h (180 microg/kg plus 2.0 microg/min.kg, and 220 microg/kg plus 2.5 microg/min.kg) in this phase I clinical trial. Plasma levels of batifiban and areas under the curve were found to be proportional to doses. Batifiban was rapidly eliminated with a half-life of approximately 2.5 h. Significant differences were noted for plasma levels of batifiban and areas under the curve between males and females. No significant differences in the terminal half-life were found between males and females. Batifiban reversibly inhibited ex vivo platelet aggregation in a dose- and concentration-dependent manner, consistent with its mechanism as a GPIIb/IIIa antagonist. Single and multiple intravenous doses of batifiban were found to be safe and well tolerated in healthy subjects. These results support a bolus injection plus intravenous infusion regimen of batifiban for the treatment and prevention of acute coronary syndromes.
authors.affiliation: Department of Infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. chenhui0515@yahoo.com.cn
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Qiao
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.forename: Jungang
authors.initials: J
authors.lastname: Deng
authors.forename: Zhirong
authors.initials: Z
authors.lastname: Tan
authors.forename: Tao
authors.initials: T
authors.lastname: Guo
authors.forename: Weiyong
authors.initials: W
authors.lastname: Li
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010456:Peptides, Cyclic / Q000493:pharmacokinetics* / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D010456:Peptides, Cyclic; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; C555443:batifiban